Given that a major hurdle in cancer treatment is the need to pinpoint the subset(s) of patients who might benefit from any emerging targeted therapy, we propose that MYC(N) hyperactivation might become a useful predictive biomarker in NUDT1-based treatment regimen. This evidence concerns the gene MYC and cancer.